Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02825459 · ClinicalTrials.gov registry record · NA
Does Abstinence From E-cigarettes Produce Withdrawal Symptoms?
A NA study of Substance Withdrawal Syndrome, sponsored by University of Vermont.
- Completed
- Registry status
- NA
- Development phase
- 147
- Enrollment target
- 2
- Study locations
NCT02825459: Completed NA study of Substance Withdrawal Syndrome, sponsored by University of Vermont.
NCT02825459 is a NA study of Substance Withdrawal Syndrome that has completed, run by University of Vermont. The registered enrollment target is 147 participants, roughly in line with the 147-participant average among 3 other Substance Withdrawal Syndrome trials with a reported enrollment target. The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02825459, a NA study of Substance Withdrawal Syndrome, has completed, sponsored by University of Vermont.
- COMPLETED
- Registry status
- NA
- Development phase
- 147 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to see whether adults who use e-cigarettes every day experience symptoms of nicotine withdrawal when they stop using e-cigarettes for 6 days.
Primary Outcome
The investigators will compare the mean score across participants for the entire 6-day abstinence vs. use conditions.
Conditions Studied
Interventions
- BEHAVIORAL Abstinence from e-cigarettes
Study Locations (2)
Maryland
- Battelle Memorial Institute - Baltimore
Vermont
- University of Vermont - Burlington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 147 participants |
| Start Date | 2016-07 |
| Est. Completion | 2018-10-31 |
| Phase | NA |
What the finished NCT02825459 record still lists
NCT02825459 is an interventional study that assigns participants to a tested intervention. The registered 147 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 147-participant average among 3 other Substance Withdrawal Syndrome trials with a reported enrollment target.
The record links to 1 condition, with Substance Withdrawal Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Abstinence from e-cigarettes is the first listed.
NCT02825459 reports a single indexed study location in Maryland, Vermont.
Frequently Asked Questions
What is clinical trial NCT02825459 about?
NCT02825459 is a clinical study titled "Does Abstinence From E-cigarettes Produce Withdrawal Symptoms?". The purpose of this study is to see whether adults who use e-cigarettes every day experience symptoms of nicotine withdrawal when they stop using e-cigarettes for 6 days.
What is the current status of trial NCT02825459?
This trial is currently completed. It is a NA study. The enrollment target is 147 participants. The study started on 2016-07. Estimated completion is 2018-10-31.
What conditions does trial NCT02825459 study?
This clinical trial studies the following conditions: Substance Withdrawal Syndrome.
What interventions are being tested in trial NCT02825459?
The interventions under investigation include: Abstinence from e-cigarettes (BEHAVIORAL).
Who is sponsoring clinical trial NCT02825459?
This trial is sponsored by University of Vermont, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02825459 being conducted?
This trial has 2 study locations across Maryland, Vermont. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Substance Withdrawal Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04396613 · 147 participants · NA
Wound Closure Techniques in Primary Spine Surgery
- NCT04851119 · 147 participants · Phase 1
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- NCT05523947 · 147 participants · Phase 1
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
- NCT06121843 · 147 participants · Phase 1
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia